More Options Available With a Quadripolar LV Lead pRovidE In-clinic Solutions to CRT Challenges
Launched by ABBOTT MEDICAL DEVICES · Jan 11, 2012
Trial Information
Current as of July 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients are indicated for Cardiac Resynchronization Therapy with Defibrillation backup device (CRT-D) implantation, as per current international certified guidelines
- • Patients age is 18 years or greater
- • Patients must indicate their understanding of the study and willingness to participate by signing the appropriate informed consent form
- • Patients must be willing and able to comply with all study requirements
- Exclusion Criteria:
- • Patients with a life expectancy \<12 months.
- • Patients who are or may potentially be pregnant.
- * Patient has suffered any of the following in the 4 weeks prior to enrolment:
- • Myocardial Infarction (MI)
- • Coronary Artery Bypass Graft (CABG)
- • Unstable Angina Pectoris
- • Patient has primary valvular disease which has not been corrected
About Abbott Medical Devices
Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rehovot, , Israel
Enschede, , Netherlands
Cardiff, , United Kingdom
Ashkelon, , Israel
Madrid, , Spain
Breda, , Netherlands
Tampere, , Finland
Tel Hashomer, , Israel
Birmingham, , United Kingdom
New Delhi, , India
Zabrze, , Poland
Bilbao, , Spain
Calgary, , Canada
Marseille, , France
Leipzig, , Germany
Bournemouth, , United Kingdom
Middlesbrough, , United Kingdom
Genk, , Belgium
Valencia, , Spain
Lecce, , Italy
Coburg, , Germany
Nantes, , France
Homburg, , Germany
Berlin, , Germany
Brest, , France
Novara, , Italy
Den Haag, , Netherlands
Den Haag, , Netherlands
Clermont Ferrand, , France
Rome, , Italy
London, , United Kingdom
Taranto, , Italy
Liège, , Belgium
Edmonton, , Canada
Halifax, , Canada
Quebec, , Canada
St. Johns, , Canada
Lahti, , Finland
Grenoble, , France
Lyon, , France
Marseille, , France
Nantes, , France
Rennes, , France
Rouen, , France
Saint Priest En Jarez, , France
Villeurbanne, , France
Berlin, , Germany
Bielefeld, , Germany
Essen, , Germany
Greifswald, , Germany
Ludenscheid, , Germany
Ludwigshafen, , Germany
Trier, , Germany
New Delhi, , India
Beer Sheba, , Israel
Bologna, , Italy
Caserta, , Italy
Catanzaro, , Italy
Torino, , Italy
Verona, , Italy
Basel, , Switzerland
Geneva, , Switzerland
Lugano, , Switzerland
Zurich, , Switzerland
Patients applied
Trial Officials
Giuseppe Boriani, Pro.
Principal Investigator
Policlinico Universitario S. Orsola e Malpighi, Bologna, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials